Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.

The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more af ...

As part of the deal, which will be completed later this year, the Chicago-based pharmacy chain will sell its VillageMD unit. Other pharmaceutical news is about Cost Plus Drug Co., Eli Lilly, and more.

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...